- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 213/50 - Ketonic radicals
Patent holdings for IPC class C07D 213/50
Total number of patents in this class: 247
10-year publication summary
25
|
24
|
30
|
13
|
16
|
17
|
14
|
7
|
5
|
2
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Syngenta Limited | 509 |
9 |
Biosplice Therapeutics, Inc. | 166 |
9 |
Syngenta Participations AG | 4970 |
6 |
PTC Therapeutics, Inc. | 492 |
6 |
Mycovia Pharmaceuticals, Inc. | 40 |
6 |
The Regents of the University of California | 18943 |
5 |
Givaudan SA | 1760 |
5 |
Johnson Matthey Public Limited Company | 1852 |
5 |
Lighthouse Pharmaceuticals, Inc. | 14 |
5 |
The Board of Trustees of the University of Illinois | 2623 |
4 |
Chem-Master International, Inc. | 9 |
4 |
Epizyme, Inc. | 383 |
4 |
Purdue Pharma L.P. | 519 |
4 |
Centre National de La Recherche Scientifique | 9632 |
3 |
Mcmaster University | 746 |
3 |
The Research Foundation of State University of New York | 507 |
3 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
3 |
Xenthera, Inc. | 4 |
3 |
Pfizer Inc. | 3322 |
2 |
Merck Patent GmbH | 5909 |
2 |
Other owners | 156 |